Ingrid E H Kremer (Ingrid Kremer)

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 13

Top Topics

Cross Sectional

Multiple Sclerosis

Top Venues

Expert review of pharmacoeconomics & outcomes research

Journal of medical Internet research

Applied health economics and health policy

This page only lists publications with an associated author ORCID identifier.

Publications

Jalal Dahham, Mickaël J C Hiligsmann, Ingrid E H Kremer, Samia Joseph Khoury, Hala Darwish, Hassan Hosseini, Silvia M A A Evers, Rana G Rizk
The societal costs of multiple sclerosis in Lebanon: a cross-sectional study. Expert review of pharmacoeconomics & outcomes research 23 (4) (2023)
Jalal Dahham, Mickaël J C Hiligsmann, Ingrid E H Kremer, Samia Joseph Khoury, Hala Darwish, Hassan Hosseini, Silvia M A A Evers, Rana G Rizk
The societal costs of multiple sclerosis in Lebanon: a cross-sectional study. Expert review of pharmacoeconomics & outcomes research (2023)
Ingrid E H Kremer, Charlotte Beaudart, Joost Simons, Hiskya Plieger, Melanie Schroeder, Mickaël J C Hiligsmann
Preferences of people living with HIV for injectable and oral antiretroviral treatment in the Netherlands: a discrete choice experiment. AIDS care (2023)
Jalal Dahham, Mickaël J C Hiligsmann, Ingrid E H Kremer, Samia Joseph Khoury, Hala Darwish, Hassan Hosseini, Silvia M A A Evers, Rana G Rizk
The societal costs of multiple sclerosis in Lebanon: a cross-sectional study. Expert review of pharmacoeconomics & outcomes research (2023)
Jalal Dahham, Mickaël J C Hiligsmann, Ingrid E H Kremer, Samia Joseph Khoury, Hala Darwish, Hassan Hosseini, Silvia M A A Evers, Rana G Rizk
The societal costs of multiple sclerosis in Lebanon: a cross-sectional study. Expert review of pharmacoeconomics & outcomes research (2023)
Jalal Dahham, Mickaël J C Hiligsmann, Ingrid E H Kremer, Samia Joseph Khoury, Hala Darwish, Hassan Hosseini, Silvia M A A Evers, Rana G Rizk
The societal costs of multiple sclerosis in Lebanon: a cross-sectional study. Expert review of pharmacoeconomics & outcomes research 23 (4) (2023)
Jalal Dahham, Ingrid E H Kremer, Mickaël J C Hiligsmann, Kamal Hamdan, Abdallah Nassereddine, Silvia M A A Evers, Rana G Rizk
Valuation of Costs in Health Economics During Financial and Economic Crises: A Case Study from Lebanon. Applied health economics and health policy (2022)
Jalal Dahham, Rana G Rizk, Ingrid E H Kremer, Silvia M A A Evers, Mickaël J C Hiligsmann
Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review. PharmacoEconomics 39 (7) (2021)
Jalal Dahham, Rana G Rizk, Mickaël J C Hiligsmann, Caroline Daccache, Samia Joseph Khoury, Hala Darwish, Silvia M A A Evers, Ingrid E H Kremer
The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol. Expert review of pharmacoeconomics & outcomes research (2021)
Ingrid E H Kremer, Mickael Hiligsmann, Josh Carlson, Marita Zimmermann, Peter J Jongen, Silvia M A A Evers, Svenja Petersohn, Xavier Ghislain Léon Victor Pouwels, Nick Bansback
Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. Medical decision making : an international journal of the Society for Medical Decision Making 40 (8) (2021)
Kei-Long Cheung, Susanne Mayer, Judit Simon, Hein de Vries, Silvia M A A Evers, Ingrid E H Kremer, Mickaël J C Hiligsmann
Comparison of statistical analysis methods for object case best-worst scaling. Journal of medical economics 22 (6) (2018)
Peter Joseph Jongen, Ingrid E H Kremer, Elena Hristodorova, Silvia M A A Evers, Anton Kool, Esther M J van Noort, Mickaël J C Hiligsmann
Adherence to Web-Based Self-Assessments in Long-Term Direct-to-Patient Research: Two-Year Study of Multiple Sclerosis Patients. Journal of medical Internet research 19 (7) (2017)
Ingrid E H Kremer, Silvia M A A Evers, Peter J Jongen, Mickaël Hiligsmann
Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: A best-worst scaling. Health expectations : an international journal of public participation in health care and health policy 21 (1) (2017)